Composition for resisting fatigue and enhancing immunity

Abstract

The invention discloses a composition for resisting fatigue and enhancing immunity. The composition is prepared from 1-5 parts by weight of thymosin peptide and 100-2500 parts by weight of rhizoma polygonati. The preparation method comprises the following steps: crushing a rhizoma polygonati raw material medicine, then performing water extraction, ultrasonic extraction and centrifugation, performing rotary evaporation on supernate obtained by centrifugation, then adding the supernate into an ethanol solution, stirring, standing, filtering, and freeze-drying the obtained precipitate to obtain the rhizoma polygonati extract. The thymosin peptide and the rhizoma polygonati extract are mixed to prepare the composition.

Description

Technical Field

[0001] The present application relates to the field of food technology, and in particular to a composition for resisting fatigue and enhancing immunity. Background Art

[0002] The immune system is the body's own defense mechanism, capable of identifying and eliminating all kinds of foreign invading substances, such as toxic substances, bacteria, and parasites, and can deal with aging, damaged, dead, and degenerated cells in the body. It can also identify and deal with mutated cells and virus-infected cells in the body.

[0003] Post-pandemic, people's demand for health has intensified. Improving immunity can help reduce the incidence of severe illness in response to various viruses. On May 18, 2023, Xinhua News Agency and By-Health released a report titled "National Immunity and Nutritional Health Status Survey," which revealed that over 90% of Chinese citizens have increased their focus on nutritional health over the past year, and nearly 80% have increased their nutritional supplements to boost their immunity. Nutrition is the foundation of immunity, and improving physical fitness and enhancing immunity has become a widely held belief.

[0004] The main drugs currently used clinically to enhance immunity are as follows:

[0005] 1. Thymosin. Thymosin is a polypeptide protein extracted primarily from the calf thymus. This type of thymosin can be used to enhance the body's cellular immunity, promoting T cell differentiation and proliferation, and T cell recognition of antigens. Thymosin is often used for patients with weak immunity, frequent colds, or tumors.

[0006] 2. Immunoglobulin mainly comes from human blood. Immunoglobulin itself is an antibody and is mainly used to treat bacterial and viral infections.

[0007] 3. Transfer factor can enhance cellular immunity and is currently only used for children's blood system diseases to prevent herpes simplex virus infection.

[0008] As people's living standards improve, the demand for healthy food increases.

[0009] Polygonatum sibiricum, a traditional Chinese medicinal herb, nourishes yin and moistens the lungs, strengthens the spleen and invigorates qi. Thymosin is a bioactive peptide with immunomodulatory properties that can enhance immunity. Combining Polygonatum sibiricum with thymosin could lead to the development of a functional food with immune-boosting and fatigue-fatigue properties, which holds great market potential.

[0010] Thymosin is a natural peptide molecule secreted by the thymus gland that exhibits multiple biological activities. It plays an important role in immunomodulation, anti-tumor, antioxidant, and anti-aging. Studies have shown that thymosin can enhance lymphocyte activity, promote the synthesis and secretion of immunoglobulins, and inhibit inflammatory responses. It also regulates the balance between T and B cells, enhancing the body's ability to fight pathogens. Furthermore, thymosin can inhibit tumor growth and spread by promoting tumor cell apoptosis, inhibiting tumor cell proliferation and migration, and regulating the expression of tumor-related genes. Furthermore, thymosin can enhance the effectiveness of chemotherapy and radiotherapy while reducing their damage to normal cells.

[0011] Polygonatum sibiricum is the dried root of Polygonatum kingianum Coll. et Hemsl. or Polygonatum sibiricum Red., both of the Liliaceae family. It has a sweet taste and a neutral nature. It enters the lung, spleen, and kidney meridians, replenishing qi and nourishing yin, strengthening the spleen and moistening the lungs. It is used to treat spleen and stomach qi deficiency, fatigue, internal heat, and thirst. Polygonatum sibiricum extract is a medicinal product obtained by extracting and concentrating the active ingredients in Polygonatum sibiricum. Its main active ingredient is Polygonatum sibiricum polysaccharide. Polygonatum sibiricum polysaccharide has a significant immunomodulatory effect, regulating the immune system through multiple immunomodulatory pathways. Numerous studies have shown that Polygonatum sibiricum polysaccharide can enhance humoral immune function and increase the levels of immunoglobulins IgG, IgA, and IgM, thereby enhancing the body's immune regulatory capacity.

[0012] The information disclosed in the background section is only intended to enhance understanding of the overall background of the invention and should not be considered as an admission or any form of suggestion that the information constitutes the prior art already known to a person of ordinary skill in the art. Summary of the Invention

[0013] In response to the above technical problems, the present application provides a composition for anti-fatigue and immune enhancement, which can improve the clearance index and phagocytosis index of immunocompromised model mice.

[0014] The present application provides a composition for resisting fatigue and enhancing immunity, which is composed of 1 to 5 parts by weight of thymosin peptide and 100 to 2500 parts by weight of polygonatum;

[0015] The preparation method comprises the following steps: crushing the raw material of polygonatum, extracting with water, ultrasonically extracting, centrifuging, rotary evaporating the supernatant obtained by centrifugation, adding the supernatant to an ethanol solution, stirring, standing, filtering, and freeze-drying the obtained precipitate to obtain the polygonatum extract;

[0016] The composition is prepared by mixing thymosin peptide and polygonatum sibiricum extract.

[0017] Preferably, the dosage of the composition for immunocompromised mouse model experimental mice is 0.35-1.4 g / kg.

[0018] Preferably, the dosage of the composition for tumor mouse model experimental mice is 0.35-1.4 g / kg.

[0019] Preferably, the dosage of the composition for immunocompromised mouse model experimental mice is 1.4 g / kg.

[0020] Preferably, the dosage of the composition for tumor mouse model experimental mice is 1.4 g / kg.

[0021] Preferably, the composition is a solid beverage, compressed candy, liquid beverage, oral liquid, capsule or tablet.

[0022] Preferably, the dosage form of the composition is solid beverage, compressed candy, liquid beverage, oral liquid, capsule or tablet.

[0023] Preferably, the water extraction is performed at 70-80° C. for 30-40 min.

[0024] The beneficial effects of this application include:

[0025] 1) The composition for anti-fatigue and immune enhancement provided in this application uses thymosin peptide and the Chinese medicinal herb Polygonatum sibiricum, which is both a medicine and a food, as raw materials. Both have a positive regulatory effect on human immunity and work synergistically with each other. Animal experiments have shown that the health product of the present invention has a significant regulatory effect on low immunity, can promote the differentiation and proliferation of T lymphocytes, and enhance autoimmunity.

[0026] 2) The composition for anti-fatigue and immune enhancement provided in the present application can significantly increase the clearance index and phagocytosis index of immunosuppressive model mice, and the high-dose group of the composition is more effective in increasing the clearance index and phagocytosis index than thymosin, indicating that the high-dose immune enhancement effect of the composition is better than thymosin.

[0027] 3) The composition for anti-fatigue and immune enhancement provided in the present application can significantly increase the serum hemolysin index of mice in the tumor model group, and the high-dose effect of the composition on increasing serum hemolysin is better than that of thymosin. DETAILED DESCRIPTION

[0028] The present invention will be further described in detail below with reference to the embodiments, but the present invention is not limited in any way. Any changes or improvements made based on the teachings of the present invention fall within the scope of protection of the present invention.

[0029] Example

[0030] Unless otherwise specified, the materials and instruments used in the following examples were obtained from commercial channels; the detection methods used were all existing methods unless otherwise specified.

[0031] Example 1 Formulations of Compositions 1 to 7

[0032] Compositions 1 to 7 were prepared according to the components and amounts shown in Table 1:

[0033] Table 1 Formulation (g)

[0034] Composition of the present invention Thymosin Polygonatum sibiricum Recipe 1 5 1500 (300 based on Polygonatum sibiricum extract) Recipe 2 5 250 (50 based on Polygonatum sibiricum extract) Recipe 3 2.5 2000 (400 based on Polygonatum sibiricum extract) Recipe 4 2.5 500 (calculated as 100g of Polygonatum sibiricum extract) Recipe 5 2.5 100 (calculated as Polygonatum sibiricum extract 20) Recipe 6 1 1500 (300 based on Polygonatum sibiricum extract) Recipe 7 1 250 (50 based on Polygonatum sibiricum extract)

[0035] The preparation method comprises: grinding a polygonatum sibiricum medicinal material into a coarse powder, mixing with water, extracting at 70-80°C for 30-40 minutes, performing ultrasonic extraction, centrifuging, rotary evaporating the supernatant obtained from the centrifugation, adding the supernatant to an ethanol solution, stirring, allowing the mixture to stand, filtering, and freeze-drying the resulting precipitate to obtain a polygonatum sibiricum extract. The polygonatum sibiricum extract and thymosin peptide are respectively weighed in the weight ratio shown in Table 1 and uniformly mixed to obtain the composition.

[0036] Example 2 Effect of the health product of the present invention on the immune function of immunocompromised mice

[0037] 1. Materials

[0038] 1.1 Experimental Animals

[0039] ICR mice, half male and half female, weighing 18-22 g, were provided by the Experimental Animal Center of Kunming Medical College, animal qualification certificate number SCXK (Yunnan) 2005-0008. Mice were purchased one week prior to the experiment and housed in a soundproofed animal room at 25-27°C with free access to food and water.

[0040] 1.2 Health products and reagents of the present invention

[0041] The health product of the present invention is named as polygonatum thymosin peptide powder (HXD).

[0042] Polygonatum thymoprotein peptide powder: prepared by the R&D center of Kunming Longjin Pharmaceutical Co., Ltd., the preparation method is shown in Example 1, and the dry extract obtained by water extraction and alcohol precipitation of Polygonatum thymoprotein peptide is mixed with thymoprotein peptide. The specific formula is Formula 4 in Example 1.

[0043] 1.3 Dosage design

[0044] The recommended dosage of Polygonatum thymosin peptide powder is: 1-2 bags per day for adults, which translates to a maximum daily dose of 4g. Based on a 60kg adult body weight, the human dose is 0.07g / kg. The equivalent dose for mice is calculated 10 times (based on body surface area), which is 0.7g / kg. In this experiment, 0.7g / kg was used as the median dose, and the high and low doses were 1.4g / kg and 0.35g / kg, respectively.

[0045] Dosage of thymosin enteric-coated tablets: 5-30 mg each time for adults, 1-3 times a day, the maximum daily dose is 90 mg. Based on an adult weighing 60 kg, the human dose is 1.5 mg / kg.

[0046] 1.4 Instruments

[0047] Electronic balance (Sartorius Scientific Instruments); UV spectrophotometer; electric constant temperature water bath; vortex mixer (Zhejiang Lecheng Electric Factory).

[0048] 2. Methods

[0049] 2.1 Grouping and Dosing

[0050] Mice were randomly divided into six groups, each consisting of 10 mice: a normal control group, an immunocompromised model group, a positive control group, and three groups of high, medium, and low doses of Polygonatum thymosin peptide powder. Each group was administered once daily for 10 consecutive days. The high, medium, and low doses of Polygonatum thymosin peptide powder were administered orally at 1.4 g / kg, 0.7 g / kg, and 0.35 g / kg, respectively. The positive control group was administered 1.5 mg / kg of thymosin enteric-coated tablets. The normal control group and the model group were administered an equal volume of saline (0.1 mL / 10 g) by gavage. Seven days after administration, all mice, except the normal control group, were intraperitoneally injected with 80 mg / kg of cyclophosphamide once daily for three consecutive days to induce an immunocompromised mouse model. The normal control group was intraperitoneally injected with an equal volume of saline (0.1 mL / 10 g).

[0051] One hour after the last administration, 0.1 mL / 10 g of 5-fold diluted India ink was injected into the tail vein of each mouse. The time was immediately started after the injection. 20 μL of blood was collected from the epicanthus venous plexus 2 minutes (t1) and 10 minutes (t2) after the injection, and added to 2 mL of 0.1% Na2CO3 solution. The mixture was shaken and the Na2CO3 solution was used as a blank control. The absorbance at t1 and t2 was measured at a wavelength of 680 nm using a 752 spectrophotometer, which were A1 and A2, respectively.

[0052] After blood collection, the mice were killed by cervical dislocation, and the liver and spleen were removed and weighed. The clearance index K and phagocytic index α were calculated. K = (log A1 - log A2) / (t2 - t1),

[0053] 2.2 Results

[0054] The results of the normal control group, immunodeficiency model group, positive control group, high-dose group, medium-dose group, and low-dose group are shown in Table 1:

[0055] Table 1. Effects of Polygonatum thymosin peptide powder on clearance index and phagocytosis index of immunocompromised mice ( n=10)

[0056]

[0057] #P<0.05, ##P<0.01, compared with the normal group; *P<0.05, **P<0.01, compared with the model group;

[0058] As can be seen from Table 1, the clearance index and phagocytosis index of the immunosuppressive model group mice were significantly reduced, and the difference was statistically significant compared with the normal control group (P<0.01), indicating that the cyclophosphamide-induced immunosuppressive model will cause a significant decrease in cellular immune function; the positive control group and the high, medium and low dose groups of Polygonatum thymoprotein peptide powder can significantly increase the clearance index and phagocytosis index of the immunosuppressive model mice, and the difference was statistically significant compared with the model group (P<0.01); and the effect of the high dose group of Polygonatum thymoprotein peptide powder in increasing the clearance index and phagocytosis index was better than that of the positive control group, indicating that the effect of high dose Polygonatum thymoprotein peptide powder in enhancing immunity is better than that of the positive control (thymosin enteric-coated tablets).

[0059] Example 3 Effect of Composition 2 on the Immune Function of Tumor Mice

[0060] Material

[0061] 1.1 Cell lines

[0062] Mouse sarcoma S180 solid type (S180) and mouse hepatocarcinoma solid type (H22) were provided by the Key Laboratory of Natural Medicine Pharmacology, Kunming Medical College, and were obtained from the cell bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.

[0063] 1.2 Experimental animals

[0064] ICR mice, half male and half female, weighing 18-22 g, were provided by the Experimental Animal Center of Kunming Medical College, animal qualification certificate number SCXK (Yunnan) 2005-0008. Mice were purchased one week prior to the experiment and housed in a soundproofed animal room at 25-27°C with free access to food and water.

[0065] 1.3 Health products and reagents of the present invention

[0066] The invention provides a health product named as polygonatum thymosin peptide powder (HXD).

[0067] Polygonatum thymoprotein peptide powder: prepared by the R&D center of Kunming Longjin Pharmaceutical Co., Ltd., the preparation method is shown in Example 1, and the dry extract obtained by water extraction and alcohol precipitation of Polygonatum thymoprotein peptide is mixed with thymoprotein peptide. The specific formula is Formula 4 in Example 1.

[0068] Sheep red blood cell (SRBC) suspension: Collect blood from the jugular vein of a healthy sheep and immediately transfer it to a sterile glass-bulb-filled Erlenmeyer flask. Gently shake thoroughly for 10-15 minutes to remove fibrin. Add Alsever solution equivalent to twice the volume of the sheep blood and shake thoroughly. Store in a refrigerator at 4°C until use. Immediately before use, remove an appropriate amount of SRBC and wash three times with sterile saline (2000 rpm for 10 minutes each time). Collect the packed red blood cells and prepare a sheep red blood cell suspension of the desired concentration with saline.

[0069] Preparation of guinea pig complement: Collect healthy guinea pig blood, separate the serum, mix, add 10 ml of guinea pig serum to every 1 ml of packed sheep red blood cells (prepared by defibrination and multiple washing), place in a 4°C refrigerator for 30 minutes, shake, centrifuge, and take the supernatant to make complement (diluted with physiological saline at a ratio of 1:10 when used).

[0070] 1.4 Dosage design

[0071] The recommended dosage of Polygonatum thymosin peptide powder is: 1-2 bags per day for adults, which translates to a maximum daily dose of 4g. Based on a 60kg adult body weight, the human dose is 0.07g / kg. The equivalent dose for mice is calculated 10 times (based on body surface area), which is 0.7g / kg. In this experiment, 0.7g / kg was used as the median dose, and the high and low doses were 1.4g / kg and 0.35g / kg, respectively.

[0072] Dosage of thymosin injection: 10-20 mg each time for adults, once a day or as directed by a doctor. The maximum daily dose for humans is 20 mg. Based on an adult weighing 60 kg, the dose for mice in the positive control group is 0.33 mg / kg.

[0073] 1.5 Instruments

[0074] Inverted microscope, Chongqing Optical Instrument Factory; clean bench, Suzhou Purification Equipment Factory; DG5031 enzyme-linked immunosorbent assay, State-owned Huadong Electron Tube Factory; CO2 incubator, Thermo Fisher Scientific; 80-2 centrifugal sedimentation chamber, Shanghai Surgical Instrument Factory; 96-well culture plate, Corning.

[0075] 2. Methods

[0076] 2.1 Grouping and Dosing

[0077] Aseptically extract the ascites of tumor-bearing mice 8 days after passage, dilute with sterile saline, and adjust the cell concentration to 5.0×107 / ml, inoculated subcutaneously in the right forelimb of mice, 0.2ml each, and randomly divided into 5 groups 24 hours after inoculation, with 10 mice in each group, namely model group, positive control group, high-dose, medium-dose and low-dose groups of Polygonatum thymosin peptide powder; another 10 mice without tumor inoculation were taken as normal control group.

[0078] Each group of mice was administered with the following method, once a day for 10 consecutive days. The high, medium and low dose groups of Polygonatum thymosin peptide powder were respectively given by gavage with 1.4g / kg, 0.7g / kg and 0.35g / kg of Polygonatum thymosin peptide powder; the positive control group was injected with 0.33mg / kg of thymosin injection; the model group and the normal control group were given an equal amount of normal saline (0.1mL / 10g) by gavage.

[0079] On the fifth day of administration, each mouse was immunized with an intraperitoneal injection of 0.2 ml of 20% SRBC. On the fifth day after immunization, 1 hour after the first administration, the eyeballs of the mice were removed and blood was collected. The blood was kept at room temperature for 1 hour and centrifuged at 2000 rpm for 10 minutes. The serum was separated and diluted 1:2 with normal saline. To the experimental tube, 250 μL of the diluted serum sample, 125 μL of 10% SRBC, and 250 μL of complement were added in sequence. To control tube 1, 125 μL of 10% SRBC, 250 μL of complement, and 250 μL of normal saline were added in sequence. To control tube 2, 125 μL of 10% SRBC, 250 μL of normal saline, and 250 μL of the diluted serum sample were added in sequence.

[0080] After incubation at 37°C for 30 minutes, the reaction was terminated on ice for 10 minutes and centrifuged at 2000 rpm for 10 minutes. 250 μL of the supernatant was added to a 96-well culture plate and the OD value at a wavelength of 540 nm was measured using a microplate reader.

[0081] 2.2 Effect of Polygonatum thymosin peptide powder on serum hemolysin in S180 tumor-bearing mice

[0082] The results of the normal control group, immunodeficiency model group, positive control group, high-dose group, medium-dose group, and low-dose group are shown in Table 2:

[0083] Table 2. Effect of Polygonatum thymosin peptide powder on serum hemolysin in S180 tumor mice ( n=10)

[0084]

[0085] #P<0.05, ##P<0.01, compared with the blank group; *P<0.05, **P<0.01, compared with the model group.

[0086] As can be seen from Table 2, the difference in serum hemolysin between the tumor model group and the normal control group was statistically significant (P<0.01), indicating that the S180 tumor mouse model would cause a significant increase in serum hemolysin cells; the positive control group, high-dose and medium-dose groups of Polygonatum thymoprotein peptide powder could significantly increase the serum hemolysin index of tumor mice, and the difference was statistically significant compared with the model group (P<0.01); and the effect of the high-dose group of Polygonatum thymoprotein peptide powder on increasing serum hemolysin was better than that of the positive control group, indicating that the effect of high-dose Polygonatum thymoprotein peptide powder on increasing serum hemolysin in tumor mice was better than that of the positive control (thymosin injection).

[0087] Example 4 Compressed Sugar Dosage Form

[0088] According to the formulation of composition 2 described in Example 1, tablet candy was prepared according to the following process:

[0089] The polygonatum sibiricum medicinal material is crushed into coarse powder, mixed with water, extracted at 70-80°C for 30-40 minutes, and then ultrasonically extracted and centrifuged. The supernatant obtained by centrifugation is rotary evaporated and then added to an ethanol solution with stirring, allowed to stand, filtered, and the obtained precipitate is freeze-dried to obtain a polygonatum sibiricum extract.

[0090] The polygonatum extract and thymosin peptide are mixed in proportion, and then 1 to 2 times the amount of a matrix is added, and the mixture is ground, sieved and tableted to obtain the product. The matrix is a sweetener, a binder and a disintegrant. The sweetener is a non-sugar sweetener such as sorbitol, the binder is starch slurry, the disintegrant is sodium carboxymethyl starch, and the seasoning is essence.

[0091] Example 5 Solid Beverage Formulation

[0092] According to the formulation of composition 4 described in Example 1, a solid beverage was prepared according to the following process:

[0093] The Polygonatum sibiricum extract is obtained by grinding the Polygonatum sibiricum extract into a coarse powder, mixing it with water, and extracting it at 70-80°C for 30-40 minutes. The extract is then ultrasonically extracted and centrifuged. The supernatant obtained by centrifugation is rotary evaporated and then added to an ethanol solution with stirring. The mixture is allowed to stand, filtered, and the resulting precipitate is freeze-dried to obtain the Polygonatum sibiricum extract. The Polygonatum sibiricum extract and thymosin peptide are mixed in a certain proportion, and then an appropriate amount of sorbitol and essence are added. The mixture is thoroughly stirred and the mixture is divided into 2g aluminum-plastic bags and sealed with a pressure seal to obtain the finished product.

[0094] Example 6 Liquid Oral Preparation

[0095] According to the formulation of composition 4 described in Example 1, a liquid oral preparation was prepared according to the following process:

[0096] The polygonatum sibiricum extract is obtained by grinding the polygonatum sibiricum into coarse powder, mixing it with water, and extracting it at 70-80°C for 30-40 minutes. The extract is then ultrasonically extracted and centrifuged. The supernatant obtained by centrifugation is rotary evaporated and then added to an ethanol solution with stirring. The mixture is allowed to stand, filtered, and the resulting precipitate is freeze-dried to obtain the polygonatum sibiricum extract. The polygonatum sibiricum extract and thymosin peptide are added to purified water in a proportioned manner and dissolved. An appropriate amount of xylitol is then added and stirred to dissolve.

[0097] Example 7 Capsule Dosage Form

[0098] According to the formulation of composition 7 described in Example 1, capsules were prepared according to the following process:

[0099] The polygonatum sibiricum extract is obtained by grinding the polygonatum sibiricum extract into a coarse powder, mixing it with water, and extracting it at 70-80°C for 30-40 minutes. The extract is then ultrasonically extracted and centrifuged. The supernatant obtained by centrifugation is rotary evaporated and then added to an ethanol solution with stirring. The mixture is allowed to stand, filtered, and the resulting precipitate is freeze-dried to obtain the polygonatum sibiricum extract. The polygonatum sibiricum extract and thymosin peptide are mixed in a certain proportion, and an appropriate amount of sorbitol is added and mixed uniformly. The mixture is then filled into soft capsules, shaped, and dried to obtain the product.

[0100] Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A composition for combating fatigue and enhancing immunity, characterized in that: The invention is composed of 1 to 5 parts by weight of thymosin peptide and 100 to 2500 parts by weight of polygonatum; The preparation method comprises the following steps: crushing the raw material of polygonatum, extracting with water, ultrasonically extracting, centrifuging, rotary evaporating the supernatant obtained by centrifugation, adding the supernatant to an ethanol solution, stirring, standing, filtering, and freeze-drying the obtained precipitate to obtain the polygonatum extract; The composition is prepared by mixing thymosin peptide and polygonatum sibiricum extract.

2. The composition for combating fatigue and enhancing immunity according to claim 1, characterized in that The dosage of the composition for immunocompromised mouse model experimental mice is 0.35-1.4 g / kg.

3. The composition for combating fatigue and enhancing immunity according to claim 1, characterized in that The dosage of the composition for tumor mouse model experimental mice is 0.35-1.4 g / kg.

4. The composition for combating fatigue and enhancing immunity according to claim 1, characterized in that The dosage of the composition for immunocompromised mouse model experimental mice is 1.4 g / kg.

5. The composition for combating fatigue and enhancing immunity according to claim 1, characterized in that The dosage of the composition for tumor mouse model experimental mice is 1.4 g / kg.

6. The composition for combating fatigue and enhancing immunity according to claim 1, characterized in that The composition is a solid beverage, compressed candy, liquid beverage, oral liquid, capsule or tablet.

7. The composition for combating fatigue and enhancing immunity according to claim 1, characterized in that The dosage form of the composition is solid beverage, compressed sugar, liquid beverage, oral liquid, capsule or tablet.

8. The composition for combating fatigue and enhancing immunity according to claim 1, characterized in that Water extraction is performed at 70-80°C for 30-40 minutes.

Images